Pro12Ala polymorphism in PPAR γ 2 associated with essential hypertension in Chinese nonagenarians/centenarians

Experimental Gerontology

Volumn 43, Issue 12, 2008, Pages 1108-1113

  Lu, Zhenchan ^a   Dong, Birong ^a   Mo, Xianming ^b   Chen, Tie ^a   Wu, Hongmei ^a   Zhang, Yanling ^a   Xiao, Hengyi ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Elder; Hypertension; Polymorphism; PPAR 2; Triglycerides

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE; CHINESE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PPAR GAMMA; RISK FACTORS; TRIGLYCERIDES;

EID: 56349143665     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2008.08.046     Document Type: Article

References (49)

1. Altshuler D., Hirschhorn J.N., Klannemark M., Lindgren C.M., Vohl M.C., Nemesh J., Lane C.R., Schaffner S.F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T.J., Daly M., Groop L., and Lander E.S. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26 (2000) 76-80
2. Bai P., Houten S.M., Huber A., Schreiber V., Watanabe M., Kiss B., de Murcia G., Auwerx J., and Murcia J.M.d. Peroxisome proliferator-activated receptor (PPAR)-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid × receptor/PPAR{gamma} heterodimer. J. Biol. Chem. 282 (2007) 37738-37746
3. Barbieri M., Bonafe M., Rizzo M.R., Ragno E., Olivieri F., Marchegiani F., Franceschi C., and Paolisso G. Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp. Gerontol. 39 (2004) 1095-1100
4. Benkirane K., Viel E.C., Amiri F., and Schiffrin E.L. Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47 (2006) 102-108
5. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002) 409-435
6. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., Alberiche M., Bonadonna R.C., and Muggeo M. Prevalence of insulin resistance in metabolic disorders - the bruneck study. Diabetes 47 (1998) 1643-1649
7. Chen S.F., Noguchi Y., Izumida T., Tatebe J., and Katayama S. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J. Hypertens. 14 (1996) 1325-1330
8. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., and Roccella E.J. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
9. Chuang L.M., Hsiung C.A., Chen Y.D.I., Ho L.T., Sheu W.H.H., Pei D., Nakatsuka C.H., Cox D., Pratt R.E., Lei H.H., and Tai T.Y. Sibling-based association study of the PPAR gamma(2) Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. J. Mol. Med. 79 (2001) 656-664
10. Cock T.A., Houten S.M., and Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep. 5 (2004) 142-147
11. Doney A.S.F., Fischer B., Leese G., Morris A.D., and Palmer C.N.A. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a go-DARTS study. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2403-2407
12. Douglas J.A., Erdos M.R., Watanabe R.M., Braun A., Johnston C.L., Oeth P., Mohlke K.L., Valle T.T., Ehnholm C., Buchanan T.A., Bergman R.N., Collins F.S., Boehnke M., and Tuomilehto J. The peroxisome poliferator-activated receptor-{gamma}2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 50 (2001) 886-890
13. Fields L.E., Burt V.L., Cutler J.A., Hughes J., Roccella E.J., and Sorlie P. The burden of adult hypertension in the United States 1999-2000 - a rising tide. Hypertension 44 (2004) 398-404
14. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. PNAS 94 (1997) 4312-4317
15. Frederiksen L., Brodbaek K., Fenger M., Jorgensen T., Borch-Johnsen K., Madsbad S., and Urhammer S.A. Studies of the Pro12Ala polymorphism of the PPAR-{gamma} gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J. Clin. Endocrinol. Metab. 87 (2002) 3989-3992
16. Gonzalez Sanchez J.L., Serrano Rios M., Fernandez Perez C., Laakso M., and Martinez Larrad M.T. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur. J. Endocrinol. 147 (2002) 495-501
17. Gouni-Berthold I., Giannakidou E., Muller-Wieland D., Faust M., Kotzka J., Berthold H.K., and Krone W. Peroxisorne proliferator-activated receptor-gamma 2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J. Hypertens. 23 (2005) 301-308
18. Hasstedt S.J., Ren Q.F., Teng K., and Elbein S.C. Effect of the peroxisome proliferator-activated receptor-{{gamma}}2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J. Clin. Endocrinol. Metab. 86 (2001) 536-541
19. Hottenga J.J., Boomsma D.I., Kupper N., Posthuma D., Snieder H., Willemsen G., and Geus E.J.C. Heritability and stability of resting blood pressure. Twin Res. Hum. Genet. 8 (2005) 499-508
20. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
21. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J(2) metabolite binds peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
22. Koh W.P., Yuan J.M., Van Den Berg D., Ingles S.A., and Yu M.C. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis 27 (2006) 1797-1802
23. Kotchen T.A., Reddy S., and Zhang H.Y. Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat. Am. J. Hypertens. 10 (1997) 1020-1026
24. Lehrke M., and Lazar M.A. The many faces of PPARgamma. Cell 123 (2005) 993-999
25. Leibovitz E., and Schiffrin E.L. PPAR activation: a new target for the treatment of hypertension. J. Cardiovasc. Pharmacol. 50 (2007) 120-125
26. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D., and for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 130 (1999) 461-470
27. Meirhaeghe A., Boreham C.A.G., Murray L.J., Richard F., Smith G.D., Young I.S., and Amouyel P. A possible role for the PPARG Pro12Ala polymorphism in preterm birth. Diabetes 56 (2007) 494-498
28. Mori H., Ikegami H., Kawaguchi Y., Seino S., Yokoi N., Takeda J., Inoue I., Seino Y., Yasuda K., Hanafusa T., Yamagata K., Awata T., Kadowaki T., Hara K., Yamada N., Gotoda T., Iwasaki N., Iwamoto Y., Sanke T., Nanjo K., Oka Y., Matsutani A., Maeda E., and Kasuga M. The Pro12-Ala substitution in PPAR-{gamma} is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50 (2001) 891-894
29. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose-tolerance and insulin-resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331 (1994) 1188-1193
30. Ogihara T., Rakugi H., Ikegami H., Mikami H., and Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood-pressure in diabetic hypertensives. Am. J. Hypertens. 8 (1995) 316-320
31. Osawa H., Tabara Y., Kawamoto R., Ohashi J., Ochi M., Onuma H., Nishida W., Yamada K., Nakura J., Kohara K., Miki T., and Makino H. Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 30 (2007) 1501-1506
32. Ostgren C.J., Lindblad U., Melander O., Melander A., Groop L., and Rastam L. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J. Hypertens. 21 (2003) 1657-1662
33. Pershadsingh H.A., Szollosi J., Benson S., Hyun W.C., Feuerstein B.G., and Kurtz T.W. Effects of ciglitazone on blood-pressure and intracellular calcium-metabolism. Hypertension 21 (1993) 1020-1023
34. Pihlajamaki J., Miettinen R., Valve R., Karjalainen L., Mykkanen L., Kuusisto J., Deeb S., Auwerx J., and Laakso M. The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 151 (2000) 567-574
35. Poirier O., Nicaud V., Cambien F., and Tiret L. The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. J. Mol. Med. 78 (2000) 346-351
36. Rodriguez-Esparragon F.J., Rodriguez-Perez J.C., Macias-Reyes A., and Alamo-Santana F. Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are associated with essential hypertension. J. Hypertens. 21 (2003) 1649-1655
37. Ruiz-Narvaez E.A., Kraft P., and Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-{gamma} gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am. J. Clin. Nutr. 86 (2007) 1238-1242
38. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Pagkalos E.M., Hitoglou-Makedou A.D., Pliakos C.I., Kazakos K.A., Yovos J.G., Zebekakis P.E., Tziolas I.M., and Tourkantonis A.N. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J. Hypertens. 22 (2004) 1769-1777
39. Sarafidis P.A., and Nilsson P.M. The effects of thiazolidinediones on blood pressure levels - a systematic review. Blood Press. 15 (2006) 135-150
40. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
41. Stefanski A., Majkowska L., Ciechanowicz A., Frankow M., Safranow K., Parczewski M., Moleda P., and Pilarska K. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J. Hum. Hypertens. 20 (2006) 684-692
42. Swarbrick M.M., Chapman C.M.L., McQuillan B.M., Hung J., Thompson P.L., and Beilby J.P. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur. J. Endocrinol. 144 (2001) 277-282
43. Tai E.S., Corella D., Deurenberg-Yap M., Adiconis X., Chew S.K., Tan C.E., and Ordovas J.M. Differential effects of the C1431T and Pro12Ala PPAR gamma gene variants on plasma lipids and diabetes risk in an Asian population. J. Lipid Res. 45 (2004) 674-685
44. Tonjes A., Scholz M., Loeffler M., and Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29 (2006) 2489-2497
45. Tontonoz P., Hu E.D., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by Ppar-gamma-2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
46. Tsai Y.S., Kim H.J., Takahashi N., Kim H.S., Hagaman J.R., Kim J.K., and Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPAR gamma. J. Clin. Invest. 114 (2004) 240-249
47. Walker A.B., Chattington P.D., Buckingham R.E., and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48 (1999) 1448-1453
48. Yagil Y., and Yagil C. The search for the genetic basis of hypertension. Curr. Opin. Nephrol. Hypertens. 14 (2005) 141-147
49. Yen C.J., Beamer B.A., Negri C., Silver K., Brown K.A., Yarnall D.P., Burns D.K., Roth J., and Shuldiner A.R. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 241 (1997) 270-274